相关实验视频

Updated: Jul 24, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

在细胞癌中准HIF-2α

Ramsha Ahmed¹, Moshe C Ornstein²

¹Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI, 53226, USA.

Current treatment options in oncology

|July 4, 2023

概括

低氧诱导因子2α (HIF-2α) 抑制剂在治疗转移性细胞癌 (mRCC) 方面表现有前途. 在早期mRCC试验中,Belzutifan是一种经批准的HIF-2α抑制剂,在早期mRCC试验中证明了有效性和耐受性,提供了新的治疗选择.

科学领域:

在瘤学瘤学.
医学科学医学科学医学科学

背景情况:

目前转移性细胞癌 (mRCC) 的治疗方法包括免疫疗法和向疗法 (VEGF-R,mTOR抑制剂).
疗法耐药性很常见,需要对mRCC.新的治疗策略.
VHL-HIF-VEGF通路在RCC病变发生过程中至关重要,它将HIF-2α确定为潜在的治疗标.

研究的目的:

评估低氧诱导因子2α (HIF-2α) 抑制剂作为转移性细胞癌 (mRCC) 的新疗法的潜力.
讨论Belzutifan在mRCC治疗中所扮演的角色,Belzutifan是一种已批准的HIF-2α抑制剂.

主要方法:

对目前的mRCC治疗环境的审查.
在RCC中分析VHL-HIF-VEGF通路.
检查早期临床试验数据的贝尔祖提凡在零星的mRCC.

主要成果:

贝尔祖提凡已被批准用于与VHL相关的RCC和瘤.
早期的试验表明,贝尔祖提凡在零星的mRCC中具有令人鼓舞的疗效和良好的耐受性.
HIF-2α抑制剂代表了对mRCC的有希望的新类药物.

结论:

包括Belzutifan在内的HIF-2α抑制剂为mRCC提供了一个合理的和潜在的有效的新治疗途径.
贝尔祖提凡可以作为单一药物或用于mRCC的组合疗法.
对HIF-2α抑制剂的进一步研究是有必要的,以扩大对mRCC患者的治疗选择.

关键词:

贝尔祖提芬是其中的一个.这就是HIF-2α.脏癌症是什么? 脏癌症是什么在MK-6482中,它是MK-6482.细胞癌是细胞癌.这是VHLVHL.

更多相关视频

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...